The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors

Zhizhu Zhang; Ann Richmond

doi:10.3389/fmolb.2021.648663

The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors

Front Mol Biosci. 2021 May 7:8:648663. doi: 10.3389/fmolb.2021.648663. eCollection 2021.

Authors

Zhizhu Zhang¹, Ann Richmond^{2

3}

Affiliations

¹ Department of Biological Sciences, Vanderbilt University, Nashville, TN, United States.
² Department of Pharmacology, Vanderbilt University, Nashville, TN, United States.
³ Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, United States.

Abstract

Dysregulation of phosphoinositide 3-kinase (PI3K) signaling is highly implicated in tumorigenesis, disease progression, and the development of resistance to the current standard of care treatments in breast cancer patients. This review discusses the role of PI3K pathway in breast cancer and evaluates the clinical development of PI3K inhibitors in both early and metastatic breast cancer settings. Further, this review examines the evidence for the potential synergistic benefit for the combination treatment of PI3K inhibition and immunotherapy in breast cancer treatment.

Keywords: MDSC; PI3K inhibition; breast cancer; immune checkpoint inhibitors; tumor immune microenvironment.

Publication types

Review

Abstract

Publication types

Grants and funding